HilleVax Inc. (HLVX)
NASDAQ: HLVX
· Real-Time Price · USD
2.09
-0.01 (-0.48%)
At close: Sep 16, 2025, 3:59 PM
Company Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines.
It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
The company is headquartered in Boston, Massachusetts.
HilleVax Inc.
| Country | United States |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Robert M. Hershberg |
Contact Details
Address: 75 State Street Boston, Massachusetts United States | |
| Website | https://www.hillevax.com |
Stock Details
| Ticker Symbol | HLVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001888012 |
| CUSIP Number | 43157M102 |
| ISIN Number | US43157M1027 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Chairman of the Board |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer |
| Shane A. Maltbie | Chief Financial Officer & Treasurer |
| Dr. Aditya Kohli Ph.D. | Co-Founder & Director |
| Paul S. Bavier J.D. | General Counsel, Secretary & Chief Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 19, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Sep 19, 2025 | 4 | Filing |
| Sep 19, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Sep 17, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Sep 17, 2025 | 4 | Filing |
| Sep 17, 2025 | S-8 POS | Filing |
| Sep 17, 2025 | POS AM | Filing |
| Sep 17, 2025 | POS AM | Filing |
| Sep 17, 2025 | 4 | Filing |
| Sep 17, 2025 | 4 | Filing |